GNLX · GENELUX Corp
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has experienced recurring losses from operations since inception and incurred a net loss of $18.4 million and cash used in operations of $12.5 million during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | $8000 | $8000 | $170K | $11.07M | |
| $22.68M | $19.85M | $19M | $12.77M | $9.08M | |
| $13.75M | $13.37M | $12.71M | $11.57M | $5M | |
| $36.43M | $33.22M | $31.7M | $24.34M | $14.08M | |
| -$36.42M | -$33.21M | -$31.7M | -$24.17M | -$3.01M | |
| — | -415175% | -396200% | -14214.71% | -27.22% | |
| — | — | — | $173K | — | |
| $603K | $711K | $700K | $182K | — | |
| $826K | $1.07M | $1.83M | -$4.13M | -$1.09M | |
| — | — | — | — | $1.1M | |
| -$35.6M | -$32.15M | -$29.87M | -$28.3M | -$5.21M | |
| — | -401812.5% | -373362.5% | -16645.29% | -47.05% | |
| -$35.6M | -$32.2M | -$29.82M | -$28.29M | -$5.21M | |
| USD/shares | -$0.86 | -$0.86 | -$0.95 | -$1.16 | -$0.57 |
| USD/shares | -$0.86 | -$0.86 | -$0.95 | -$1.16 | -$0.57 |
| shares | — | 37.18M | 31.45M | 31.45M | 9.12M |
| shares | — | 37.18M | 31.45M | 24.43M | 9.12M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 304 similar-size Biotechnology companies (of 537 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating and Reportable Segments | $8,000 | $8,000 | $170,000 |